Why the study?
While SGLT-2 inhibitors reduce heart failure hospitalizations in diabetes and heart failure, findings in patients with chronic kidney disease are not uniform.
Do SGLT-2 inhibitors reduce the risk of hospitalization or urgent visit for worsening heart failure in patients with chronic kidney disease?
Do SGLT-2 inhibitors reduce the risk of hospitalization or urgent visit for worsening heart failure in patients with chronic kidney disease?
SGLT-2 inhibitors significantly reduce the risk of heart failure events in patients with chronic kidney disease, with a more prominent effect in those with eGFR <60 ml/min/1.73 m2.
Answers are grounded in this paper and cite their sources.
SGLT2 inhibitors may reduce HF events in CKD; leaves open effects across baseline kidney function subgroups.
AIMS: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors significantly reduce the risk for hospitalizations for heart failure (HF) in patients with diabetes, and HF; findings in patients with chronic kidney disease (CKD) are not uniform. We aimed to perform a meta-analysis exploring the effect of SGLT-2 inhibitors on HF events in patients with CKD and across subgroups defined by baseline kidney function. METHODS AND RESULTS: A systematic search in major electronic databases was performed. Randomized controlled trials (RCTs) providing data on the effect of SGLT-2 inhibitors on the primary outcome, time to hospitalization or urgent visit for worsening HF in patients with prevalent CKD at baseline or across subgroups stratified by baseline estimated glomerular-filtration-rate (eGFR) were included. Twelve studies (n = 89,191 participants) were included in the meta-analysis. In patients with CKD, treatment with SGLT-2 inhibitors reduced the risk for HF events by 32% compared to placebo [hazard ratio (HR) 0.68; 95% confidence interval (CI) 0.63-0.73]. Reduction in HF events with SGLT-2 inhibitors was more prominent in patients with eGFR <60 ml/min/1.73 m2 (HR 0.68; 95% CI 0.62-0.74) than in those with eGFR ≥60 ml/min/1.73 m2 (HR 0.76; 95% CI 0.69-0.83). Subgroup analysis according to type of SGLT-2 inhibitor showed a consistent treatment effect across all studied agents (p-subgroup-analysis = 0.44). Sensitivity analysis including data from studies including only diabetic patients showed an even more pronounced effect in eGFR subgroup <60 ml/min/1.73 m2 (HR 0.62; 95% CI 0.54-0.70). CONCLUSION: Treatment with SGLT-2 inhibitors led to a significant reduction in HF events in patients with CKD. Such findings may change the landscape of prevention of HF events in patients with advanced CKD. PROSPERO Registration number CRD42022382857.
No takes yet. Share an insight, caveat, or question.
Theodorakopoulou et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: